Type 2 Diabetes Patients With Renal Impairment

Inclusion Criteria: * Aged ≥ 19 years at the time of screening test * Body weight of ≥ 50.0 kg to ≤ 90.0 with a body mass index (BMI) of ≥ 20.0 to ≤ 45.0 * Have been diagnosed with type 2 diabetes Exclusion Criteria: * Have clinically uncontrolled or unstable hepatic, neurological, immune system, respiratory, hemato-oncology, cardiovascular, or psychiatric disorder (subject with chronic disease such as hypertension, diabetes, and hyperlipidemia that is well controlled or stable is eligible to participate in the study based on investigator's judgement) * History of gastrointestinal diseases, dialysis, kidney transplantation, HIV, hepatitis B or C, acute or chronic infection, recent diabetic ketoacidosis, or gastrointestinal surgery that may affect the absorption of the study drug * Received SGLT2 inhibitors or drugs of thiazolidinedione class within 6 weeks of scheduled IP administration day * Clinical laboratory test values are outside the accepted normal range at screening * AST (SGOT), ALT (SGPT) \> 2 x the upper limit of normal * Repeatedly confirmed QTc interval \> 450 ms * Sitting systolic blood pressure \< 80 mmHg or \> 180 mmHg or sitting diastolic blood pressure \< 60 mmHg or \> 110 mmHg after resting for more than 3 minutes * Other exclusive inclusion criteria, as defined in the protocol